IRIS
MIGLINO, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.947
Totale 8.947
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.947
Totale 8.947
Salva come PNG Salva come JPEG
Città #
Genova 6.720
Rapallo 1.231
Genoa 965
Bordighera 31
Totale 8.947
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 162
A novel Bim-BH3-derived Bcl-X(L) inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity 143
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 143
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 141
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 134
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 134
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 132
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 132
Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. 130
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 127
Thalidomide in agnogenic and secondary myelofibrosis 127
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 127
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 126
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 123
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 123
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 122
Molecular analysis of clonality in plasma cell dyscrasias. 121
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 121
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 120
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 119
Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome. 118
Molecular analysis of the bcr rearrangement in a case of Ph'-negative blastic crisis of Ph'-positive chronic myelogenous leukemia. 117
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 117
Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration 117
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 116
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 116
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 116
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 115
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 115
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 115
Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia. 113
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 110
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 110
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia 108
Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. 107
Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. 107
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 106
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 106
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 105
Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: A translational18F-FDG PET/CT observation 105
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 104
Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia 104
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 104
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 104
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 103
Polyclonal pattern of X-inactivation in multiple myeloma. 102
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. 102
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 102
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 101
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 100
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 100
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 99
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 99
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 99
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 94
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. 86
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 86
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline 86
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing and allogeneic bone marrow transplant 84
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 84
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 82
Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: A case report 82
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 80
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. 80
Clonal analysis of hematologic malignancies using Mediterranean G6PD mosaicism. 79
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 78
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 78
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11 77
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway 77
FRONT-LINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB AND INTERFERON-ALPHA: 5-YEAR OUTCOME. 75
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 74
A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Biochemical characterization and mosaicism expression in the heterozygote. 70
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with Imatinib mesylate. 69
Vdelta1 T lymhocites from B-CLL patients recognize ULPB3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 67
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 67
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. 67
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 66
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 66
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 65
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 63
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 57
Impact of hematological malignancies in patients undergoing cardiac surgery 56
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines 55
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 54
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 53
Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. 53
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 53
Leucemia mieloide acuta Profilo genetico 51
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 51
Epigenetic Regulation in Myelodysplastic Syndrome as A Consequence of A MicroRNA Dysregulation 49
Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department 46
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 45
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 40
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 40
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 39
Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features 27
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 19
Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature 18
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 16
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 15
Totale 9.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.091
article - articoli 24.554
book - libri 0
conference - conferenze 179
curatela - curatele 0
other - altro 229
patent - brevetti 0
selected - selezionate 0
volume - volumi 129
Totale 50.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019464 0 0 0 0 0 0 0 0 0 94 204 166
2019/20202.457 98 65 96 199 236 288 372 169 229 381 238 86
2020/2021801 34 63 53 48 90 62 42 72 77 96 61 103
2021/20221.206 34 77 87 140 48 85 74 249 67 111 54 180
2022/20231.475 133 126 35 170 250 247 4 104 211 26 146 23
2023/2024768 48 81 24 109 74 208 68 116 30 10 0 0
Totale 9.122